| Syrah Resources Limited (SYR) ORDINARY FULLY PAID |
Materials |
$244 |
Change of Director's Interest Notices x3
|
29 Aug 2025 4:17PM |
$0.300 |
$0.105 |
fallen by
65%
|
|
| OMG Group Limited (OMG) ORDINARY FULLY PAID |
Consumer Staple |
$7 |
Appendix 4G and Corporate Governance Statement
|
29 Aug 2025 4:16PM |
$0.014 |
$0.007 |
fallen by
50%
|
|
| IODM Limited (IOD) ORDINARY FULLY PAID |
Information Technology |
$58 |
Appendix 4G
|
29 Aug 2025 4:16PM |
$0.100 |
$0.091 |
fallen by
9%
|
|
| Clime Capital Limited (CAM) ORDINARY FULLY PAID |
Financials |
$95 |
Notification of cessation of securities - CAM
|
29 Aug 2025 4:16PM |
$0.700 |
$0.675 |
fallen by
3.57%
|
|
| EZZ Life Science Holdings Limited (EZZ) ORDINARY FULLY PAID |
Health Care |
$22 |
Appendix 4E - Preliminary Final Report
|
29 Aug 2025 4:16PM |
$2.350 |
$0.465 |
fallen by
80.21%
|
|
EZZ - Price-sensitive ASX Announcement
Full Release
Key Points
- EZZ Life Science Holdings Limited reported a profit for the year of $6,730,441 in 2025, compared to $6,964,488 in 2024.
- The company's net assets increased from $21,322,838 in 2024 to $28,085,315 in 2025.
- Share capital rose from $6,852,670 in 2024 to $8,736,775 in 2025 due to employee incentive schemes and performance rights exercises.
- The net tangible assets per ordinary security increased from 47.98 cents in 2024 to 59.49 cents in 2025.
- The company declared a final dividend of 2.00 cents per security, fully franked, payable in December 2024, and an interim dividend of 2.00 cents per security in 2025.
- The Appendix 4E report does not report any changes in control over entities or loss of control over any entity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EZZ Life Science Holdings Limited (EZZ) ORDINARY FULLY PAID |
Health Care |
$22 |
Appendix 4E - Preliminary Final Report
|
29 Aug 2025 4:16PM |
$2.350 |
$0.465 |
fallen by
80.21%
|
|
EZZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues from ordinary activities increased by 0.65% to $66,873,691.
- Profit after tax attributable to owners decreased by 3.36% to $6,730,441.
- Net assets increased from $21,322,838 to $28,085,315.
- Share capital increased due to employee incentives and performance rights.
- Net tangible assets per security increased from 47.98 to 59.49 cents.
- Final dividend of 2.00 cents per security was paid on 9 December 2024.
- Interim dividend of 2.00 cents was paid on 17 June 2025.
- The financial statements were audited with an unmodified opinion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Thorney Opportunities Ltd (TOP) ORDINARY FULLY PAID |
Financials |
$96 |
Notification of cessation of securities - TOP
|
29 Aug 2025 4:14PM |
$0.690 |
$0.570 |
fallen by
17.39%
|
|
| Mammoth Minerals Limited (M79) ORDINARY FULLY PAID |
Materials |
$21 |
Notification regarding unquoted securities - M79
|
29 Aug 2025 4:14PM |
$0.120 |
$0.038 |
fallen by
68.33%
|
|
| IODM Limited (IOD) ORDINARY FULLY PAID |
Information Technology |
$58 |
Appendix 4E Annual Report FY25
|
29 Aug 2025 4:13PM |
$0.100 |
$0.091 |
fallen by
9%
|
|
IOD - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing ordinary activities decreased by 94% to $4,000.
- Total income from continuing ordinary activities decreased by 47% to $532,000.
- Loss from continuing operations increased by 11% to $4,942,000.
- No dividend was declared for the current or previous corresponding period.
- Net tangible liabilities were reported at (0.2) cents per share.
- Net tangible liabilities per ordinary security remained stable at (0.2) cents.
- The company did not gain control over any new entities during the period.
- The report was compiled using the International Financial Reporting Standards (IFRS).
- The strategic focus is on the commercialisation of the Felixâ„¢ male fertility technology.
- Dr. Lindley Edwards was appointed as the Non-Executive Chairperson in November 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cardiex Limited (CDX) ORDINARY FULLY PAID |
Health Care |
$20 |
FY25 Preliminary Results Summary and Company Update
|
29 Aug 2025 4:13PM |
$0.031 |
$0.036 |
risen by
16.13%
|
|
CDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Cardiex reported a 10% revenue increase in FY25.
- The company launched the Pulse product in H2 FY25.
- Operational cost reductions significantly lowered the annual expense base.
- Cash at hand by 30 June 2025 was $2.4 million, with more expected inflows.
- Net assets increased by 37% to $5.6 million.
- C2 Ventures confirmed full participation in the June Placement.
- The company is positioned to execute its FY26 growth strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mammoth Minerals Limited (M79) ORDINARY FULLY PAID |
Materials |
$21 |
Notification regarding unquoted securities - M79
|
29 Aug 2025 4:13PM |
$0.120 |
$0.038 |
fallen by
68.33%
|
|
| Cardiex Limited (CDX) ORDINARY FULLY PAID |
Health Care |
$20 |
FY25 Preliminary Results Summary and Company Update
|
29 Aug 2025 4:13PM |
$0.031 |
$0.036 |
risen by
16.13%
|
|
CDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Cardiex achieved a 10% revenue increase in FY25.
- The company's expense base was reduced to $10-12 million annually.
- Cardiex had $2.4 million in cash as of 30 June 2025.
- Expected further inflows from a June placement and R&D incentives.
- Net assets increased by 37% to $5.6 million.
- Support from C2 Ventures for future capital needs.
- New revenue streams from Pulse and Xcel products.
- Focus on executing FY26 growth strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Develop Global Limited (DVP) ORDINARY FULLY PAID |
Materials |
$1,561 |
Date of AGM and Closing Date for Director Nominations
|
29 Aug 2025 4:13PM |
$3.860 |
$4.730 |
risen by
22.54%
|
|
| Seafarms Group Limited (SFG) ORDINARY FULLY PAID |
Consumer Staple |
$10 |
SFG Preliminary Final Report FY25
|
29 Aug 2025 4:12PM |
$0.002 |
$0.002 |
risen by
33.33%
|
|
SFG - Price-sensitive ASX Announcement
Full Release
Key Points
- Seafarms Group reported a net loss of $11.7 million for FY25.
- Total equity decreased significantly to $3.1 million by June 30, 2025.
- Accumulated losses reached $312 million at the end of the financial year.
- Operating activities resulted in a cash deficit of $9.7 million.
- Asset sales and borrowings were crucial for liquidity maintenance.
- Impairments were recorded on receivables and right-of-use assets.
- Significant legal and finance costs impacted financial results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sparc Technologies Limited (SPN) ORDINARY FULLY PAID |
Materials |
$26 |
Notice Required Under ASX Listing Rule 3.13.1
|
29 Aug 2025 4:11PM |
$0.150 |
$0.215 |
risen by
43.33%
|
|
| Retail Food Group Limited (RFG) ORDINARY FULLY PAID |
Consumer Discretionary |
$68 |
Change of Director's Interest Notice
|
29 Aug 2025 4:11PM |
$1.415 |
$1.080 |
fallen by
23.67%
|
|
| Cardiex Limited (CDX) ORDINARY FULLY PAID |
Health Care |
$20 |
Appendix 4E
|
29 Aug 2025 4:11PM |
$0.031 |
$0.036 |
risen by
16.13%
|
|
CDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss for the year 2025 was AUD 13.23 million.
- Revenue decreased significantly to AUD 3.55 million.
- Cash used in operating activities increased to AUD 10.9 million.
- Financing activities provided AUD 12.87 million.
- Equity increased to AUD 5.6 million.
- Focus on medical technology for vascular health.
- No dividends were paid or proposed in 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cardiex Limited (CDX) ORDINARY FULLY PAID |
Health Care |
$20 |
Appendix 4E
|
29 Aug 2025 4:11PM |
$0.031 |
$0.036 |
risen by
16.13%
|
|
CDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for the year ended 30 June 2025 was $3,551,284, a 67% decrease from the previous year.
- The net loss for the period increased by 95% to $13,225,635.
- The decrease in revenue was partly due to the prior year's revenue including $7,669,307 from the Clinichain clinical trial.
- There was an increase in other income by 25% to $2,731,340, attributed to the RADx prize and increased R&D tax incentive income.
- Marketing and sales expenses increased by 79% due to the new Pulse device.
- A decrease in product development expenditure by 11% and administration expenses by 29%.
- Current assets increased by 17%, driven by a 405% increase in cash and cash equivalents.
- Cardiex issued 255,905,749 new shares during the year.
- Net cash used in operating activities was $10,896,357, with a significant decrease in receipts from customers.
- No dividends were paid or proposed during the financial year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Andean Silver Limited (ASL) ORDINARY FULLY PAID |
Materials |
$464 |
Restricted shares to be released from escrow
|
29 Aug 2025 4:10PM |
$1.475 |
$2.180 |
risen by
47.80%
|
|
| MAAS Group Holdings Limited (MGH) ORDINARY FULLY PAID |
Industrials |
$2,027 |
Change of Director's Interest Notice
|
29 Aug 2025 4:09PM |
$4.470 |
$5.610 |
risen by
25.50%
|
|
| EVE Health Group Limited (EVE) ORDINARY FULLY PAID |
Consumer Staple |
$6 |
Appendix 4G and Corporate Governance Statement
|
29 Aug 2025 4:09PM |
$0.032 |
$0.016 |
fallen by
50%
|
|
| Rent.com.au Limited (RNT) ORDINARY FULLY PAID |
Communication Services |
$78 |
Proposed issue of securities - RNT
|
29 Aug 2025 4:09PM |
$0.037 |
$0.067 |
risen by
81.08%
|
|
| Cettire Limited (CTT) ORDINARY FULLY PAID |
Consumer Discretionary |
$101 |
Final Director's Interest Notice
|
29 Aug 2025 4:08PM |
$0.310 |
$0.265 |
fallen by
14.52%
|
|
| EVE Health Group Limited (EVE) ORDINARY FULLY PAID |
Consumer Staple |
$6 |
Annual Report to shareholders
|
29 Aug 2025 4:08PM |
$0.032 |
$0.016 |
fallen by
50%
|
|
| EVE Health Group Limited (EVE) ORDINARY FULLY PAID |
Consumer Staple |
$6 |
Appendix 4E
|
29 Aug 2025 4:08PM |
$0.032 |
$0.016 |
fallen by
50%
|
|
EVE - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from ordinary activities decreased by 19% to AUD 1,734,726.
- Loss after tax from continuing operations decreased by 6% to AUD 1,452,957.
- Loss after tax from discontinued operations decreased significantly by 64% to AUD 126,998.
- Net loss for the period decreased by 17% to AUD 1,579,955.
- Net tangible assets per security is AUD 0.0023.
- No dividends were paid, declared, or determined during the reporting period.
- The report is supported by audited financial statements.
- EVE Health Group focuses on wellness and pharmaceutical products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.